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Dr. Ohtahara’s discussion addressed the results of
a postmarketing study of adverse events reported
by Japanese patients treated with zonisamide
monotherapy and polytherapy. The 1512 study par-
ticipants included both adults and children with
partial and generalized seizures and no previous
zonisamide treatment. Adverse effects were re-
ported and categorized by each participating physi-
cian and ranked, according to a predetermined
scale. The adverse effects and teratogenicity were
compared with the results from the zonisamide
developmental trial.
Because of the benzisoxazole-based chemical
structure of zonisamide, adverse effects similar to
other currently used antiepileptic drugs may be ex-
pected. However, Dr. Ohtahara did not anticipate
the adverse effects of zonisamide therapy to be
more severe than those noted in other antiepilepsy
drugs.
This expectation was supported in the postmar-
keting study in which 476 (31.5%) participants re-
ported 1089 adverse effects. This rate was lower
than the 51.3% adverse effect rate reported in the
premarketing trial. The most frequently reported
adverse effects in Dr. Ohtahara’s study included
psychiatric, gastrointestinal, central and periph-
eral neurological symptoms, and hypohidrosis.
However, it is the documented cases of terato-
genicity that stand out as warranting concern and
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further study. Animal studies of the carbonic an-
hydrase inhibitors such as zonisamide have been
shown to cause fetal abnormalities at blood lev-
els similar to those found in the human population.
Data from Dr. Ohtahara’s presentation supported
these ﬁndings. Within the study population, four
women were treated with zonisamide polytherapy
and 2 delivered babies with fetal abnormalities. For
this reason, we need additional data in that arena.
More information is also needed on the subject of
hypohidrosis andweight loss resulting from anorexia
associated with zonisamide treatment. Some valu-
able information can be obtained by asking our pa-
tients speciﬁc questions about the severity and on-
set of these symptoms.
For example, it is important to know when the
sweating and fever associated with hypohidrosis
occur, which patients are at the greatest risk,
and which treatments are most effective. These
are important details because as dose-related ad-
verse effects are treated much differently than
idiopathic effects, which may require the drug to
be stopped immediately. These patient-centered
questions should be more clearly deﬁned in the
coming months.
Overall, the 10 years of Japanese experience with
zonisamide combined with the current US studies
provide a solid framework for the future use of zon-
isamide in the United States.
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